Elsevier Overview
Pro stress-test →Elsevier is a Dutch academic publishing company specializing in scientific, technical, and medical content. Its products include journals such as The Lancet, Cell, the ScienceDirect collection of electronic journals, Scopus, and ClinicalKey, serving more than 30 million scientists, health professionals, and students globally. As of June 2026, the company has accelerated its expansion beyond traditional publishing into healthcare analytics and AI-powered research tools through acquisitions including Mytonomy and Wellsheet, and expansion of LeapSpace with agentic AI capabilities.
Strategic Profile
Pro stress-test →Elsevier is part of the RELX Group, a publicly traded company. The company maintains a dominant market position through highly-cited flagship journals and comprehensive research platforms. In recent years—likely in response to increased interest in open access, moderation of journal pricing, and other factors in the scholarly publishing industry—Elsevier has diversified its portfolio to include tools and services that tap into other aspects of the research process.
Competitive Landscape
Pro stress-test →Elsevier faces competition from Springer Nature and Wiley in academic publishing, Clarivate Analytics and Dimensions.ai in research analytics, and emerging players in clinical decision support and healthcare AI. The company's dominance is anchored in high-citation flagship journals and integrated information platforms that create switching costs, but open-access mandates and AI-driven alternatives pose structural disruption risks.
Industry Context
Elsevier operates in Academic and Scientific Publishing.
Key facts
Founded: 1880 · Headquarters: Amsterdam, Netherlands · Employees: 13,000 · Revenue: $5B (April 2026) · Market cap: N/A